Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL). Group 1 received vorinostat 400 mg daily, group 2 received vorinostat 300 mg twice daily for 3 days with 4 days...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Duvic, Madeleine, Talpur, Rakshandra, Ni, Xiao, Zhang, Chunlei, Hazarika, Parul, Kelly, Cecilia, Chiao, Judy H., Reilly, John F., Ricker, Justin L., Richon, Victoria M., Frankel, Stanley R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1785068/
https://ncbi.nlm.nih.gov/pubmed/16960145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-06-025999
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados